Scarica l'app Stockscreener
16.60
1.78%
-0.30
Dopo l'orario di chiusura:
17.00
0.40
+2.41%
Precedente Chiudi:
$16.90
Aprire:
$17
Volume 24 ore:
1.79M
Relative Volume:
2.00
Capitalizzazione di mercato:
$1.77B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-5.3722
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
+9.50%
1M Prestazione:
+41.28%
6M Prestazione:
+111.46%
1 anno Prestazione:
-7.05%
Intervallo 1D:
$16.17
$17.67
Intervallo di 1 settimana:
$14.26
$17.67
Portata 52W:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
16.60 | 1.66B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences Hits Day High with Strong 8.19% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with 13.97% Surge Amid Market Decline - Markets Mojo
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets - Seeking Alpha
Arcus data throw TIGIT a lifeline: Clinical Report - BioCentury
What dividend safety score for Arcus Biosciences Inc. stockMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Applying sector rotation models to Arcus Biosciences Inc.Weekly Investment Recap & Daily Stock Momentum Reports - newser.com
Why Arcus Biosciences Inc. stock is rated strong buyMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
Arcus’s ‘Last TIGIT Standing’ Shows Phase II Survival Benefit - insights.citeline.com
Arcus Biosciences reports Phase 2 survival data for gastric cancer study - Investing.com Canada
Arcus Biosciences Reports Promising Phase 2 Study Results - TipRanks
Arcus Biosciences reports Phase 2 survival data for gastric cancer study By Investing.com - Investing.com South Africa
Arcus Biosciences Announces Phase 2 Study Results - TradingView
Will Arcus Biosciences Inc. outperform the marketQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Visual analytics tools that track Arcus Biosciences Inc. performanceQuarterly Earnings Report & Weekly Consistent Profit Watchlists - newser.com
Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter
Arcus Biosciences (RCUS) Is Up 14.9% After Positive Phase 2 Survival Data in Gastric Cancer—What's Changed - Yahoo Finance
Citigroup Raises Price Target for RCUS to $54, Maintains Buy Rat - GuruFocus
Arcus Biosciences stock rises after strong gastric cancer survival data - Investing.com
Arcus Biosciences (RCUS) Shares Surge Following Positive Study R - GuruFocus
Arcus Biosciences rises on results from domvanalimab cancer study - Seeking Alpha
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
What MACD signals say about Arcus Biosciences Inc.2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Sector Update: Health Care Stocks Higher Premarket Monday - MarketScreener
Arcus Biosciences (RCUS) Reveals Promising Phase 2 Gastric Cance - GuruFocus
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ - Stocktwits
Arcus Biosciences to present promising gastric cancer survival data - Investing.com
Arcus Bioscience announces first overall survival results from phase 2 edge-gastric study - MarketScreener
Arcus Biosciences Shows 26.7‑Month Median OS in EDGE‑Gastric | RCUS Stock News - Stock Titan
Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Price momentum metrics for Arcus Biosciences Inc. explainedWeekly Trend Summary & AI Driven Price Predictions - newser.com
Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 37,792 Shares of Stock - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - MarketScreener
60,300 Options at $15.05 — Arcus Biosciences Grants 30,150 RSUs under 2020 Inducement Plan - Stock Titan
Arcus Biosciences Hits Day High with Strong 7.27% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge - Markets Mojo
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data By Investing.com - Investing.com Australia
Arcus Biosciences COO Jarrett sells $750k in shares By Investing.com - Investing.com Canada
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data - Investing.com India
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS) - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Arcus Biosciences stock By Investing.com - Investing.com Canada
RCUS: Truist Securities Raises Price Target for Arcus Biosciences | RCUS Stock News - GuruFocus
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment - inkl
A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives - Yahoo Finance
Arcus Biosciences announces new anti-inflammation programs - BioWorld MedTech
Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating - MarketScreener
Arcus Biosciences Presents Promising ARC-20 Study Data - MSN
Why Is Arcus Biosciences Stock Trading Higher On Monday? - Sahm
Arcus Biosciences (NYSE:RCUS) Trading Up 15.2%Here's What Happened - MarketBeat
Transcript : Arcus Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Arcus Biosciences (RCUS) Sees Promising Results in Latest Study - GuruFocus
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):